Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mindset Pharma Inc
(OP:
MSSTF
)
N/A
UNCHANGED
Last Price
Updated: 3:55 PM EDT, Oct 24, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mindset Pharma Inc
< Previous
1
2
3
4
Next >
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
September 18, 2023
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic...
Via
Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
August 31, 2023
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...
Via
Benzinga
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
July 18, 2023
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also...
Via
Benzinga
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
July 17, 2023
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution...
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
June 29, 2023
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the...
Via
Benzinga
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
June 27, 2023
Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K.
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
April 26, 2023
Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way.
Via
Benzinga
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
April 25, 2023
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual...
Via
Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
March 14, 2023
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.
Via
Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
March 13, 2023
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial
Via
Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
March 06, 2023
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.
Via
Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
February 03, 2023
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders
Via
Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
January 21, 2023
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...
Via
Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Via
Benzinga
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
November 16, 2022
Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc.
Via
Benzinga
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
November 16, 2022
PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers
From
PharmAla Biotech
Via
GlobeNewswire
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
November 07, 2022
(Part four of a four-part series) See previous stories in this series:
Via
Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
October 11, 2022
UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used...
Via
Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
October 07, 2022
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy
Via
Benzinga
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
October 07, 2022
Biopharma R&D company Mindset Pharma Inc.
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
September 27, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
September 27, 2022
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.
Via
Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
September 14, 2022
Biotech drug discovery firm Mindset Pharma Inc.
Via
Benzinga
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
September 07, 2022
Psychedelics R&D company Mindset Pharma (OTCQB: MSSTF) has filed no less than 16 national applications, including countries within the main South East Asian markets, for one of its key families of...
Via
Benzinga
Psychedelic Stock Gainers And Losers From September 7, 2022
September 07, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.66% at $1.12
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.